Why I Bought again at the bottom here and loaded up on Call Options for JAN.
It is unreasonable to draw conclusions about any limits to the long-term efficacy of ANAVEX 2-73 based on the interim Phase 2a findings, especially since no statistically significant decline from baseline was reported, which is impressive more than impressive. Having a dad with Alzheimer’s disease this is the company calling to me for some reason.
I believe the panic that happened was planed and shorts will cover as it goes back up. At this level nothing should hold it down and perfect timing for a partner or buyout. What I really want is my dad to get back to normal and this could be the cure.
However, this analysis was based on pooled data from a relatively small number of subjects receiving a variety of doses. It is therefore unlikely that these findings reflect the full potential ANAVEX 2-73 in treating Alzheimer’s disease. It is unreasonable to draw conclusions about any limits to the long-term efficacy of ANAVEX 2-73 based on the interim Phase 2a findings, especially since no statistically significant decline from baseline was reported, which is impressive. Detailed pre-planned analysis of the pharmacodynamic results is in progress, which is one of the key factors of relevance for regulatory agencies and which will also determine the optimal dose for future studies.”
This proof-of-concept study of 32 patients with mild-to-moderate Alzheimer’s disease (AD) demonstrated a favorable safety and tolerability/risk profile for ANAVEX 2-73, which activates the stressreducing and survival protein, the Sigma-1 receptor. Presented here is preliminary exploratory efficacy data through 31 weeks (26-week PART B including 5-week PART A) from the randomized (into different treatment regimes) open-label study with ANAVEX 2-73 oral daily dosing ranging from 10mg to 50mg (not optimized in PART B). Further analysis will be performed.
